Detalle Publicación


Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

Autores: Oriol, A. (Autor de correspondencia); Vives, S.; Hernández-Rivas, J. M.; Tormo, M.; Heras, I.; Rivas, C.; Bethencourt, C.; Moscardo, F.; Bueno, J.; Grande García, Carlos; del Potro, E.; Guardia, R.; Brunet, S.; Bergua, J.; Bernal, T.; Moreno, M. J.; Calvo, C.; Bastida, P.; Feliu, E.; Ribera, J. M.; Programa Espanol Tratamiento Hemat
ISSN: 1592-8721
Volumen: 95
Número: 4
Páginas: 589 - 596
Fecha de publicación: 2010
Background About one half of adults with acute lymphoblastic leukemia are not cured of the disease and ultimately die. The objective of this study was to explore the factors influencing the outcome of adult patients with relapsed acute lymphoblastic leukemia. Design and Methods We analyzed the characteristics, the outcome and the prognostic factors for survival after first relapse in a series of 263 adult patients with acute lymphoblastic leukemia (excluding those with mature B-cell acute lymphoblastic leukemia) prospectively enrolled in four consecutive risk-adapted PETHEMA trials. Results The median overall survival after relapse was 4.5 months (95% CI, 4-5 months) with a 5-year overall survival of 10% (95% CI, 8%-12%); 45% of patients receiving intensive second-line treatment achieved a second complete remission and 22% (95% CI, 14%-30%) of them remained disease free at 5 years. Factors predicting a good outcome after rescue therapy were age less than 30 years (2-year overall survival of 21% versus 10% for those over 30 years old; P<0.022) and a first remission lasting more than 2 years (2-year overall survival of 36% versus 17% among those with a shorter first remission; P<0.001). Patients under 30 years old whose first complete remission lasted longer than 2 years had a 5-year overall survival of 38% (95% CI, 23%-53%) and a 5-year disease-free survival of 53% (95% CI, 34%-72%). Conclusions The prognosis of adult patients with acute lymphoblastic leukemia who relapse ...